Literature DB >> 22740564

Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes.

Sabine Tischer1, Till Kaireit, Constança Figueiredo, Oliver Hiller, Britta Maecker-Kolhoff, Renè Geyeregger, Stephan Immenschuh, Rainer Blasczyk, Britta Eiz-Vesper.   

Abstract

Multimers of soluble peptide-major histocompatibilty complex (pMHC) molecules are used in both basic and clinical immunology. They allow the specific visualization and isolation of antigen-specific T cells from ex vivo samples. Adoptive transfer of antigen-specific T cells sorted by pMHC multimers is an effective strategy for treatment of patients with malignancies or infectious diseases after transplantation. We developed a new reversible pMHC multimer called 'Histamer' to enable the specific detection and isolation of antiviral T cells from peripheral blood. HLA-A*02:01/CMVpp65 (495-503) Histamer (A02/CMV Histamer) was generated by coupling 6xHis-tagged pMHC molecules onto cobalt-based magnetic beads. The specificity of the Histamer was evaluated by flow cytometry. Sorting of antiviral CD8(+) cytotoxic T lymphocytes (CTLs) was performed by magnetic cell separation, followed by the monomerization of the Histamer after addition of the competitor L-histidine. Sorted T cells were analyzed for phenotype and function. The reversible pMHC Histamer proved to be highly specific and sensitive. CMV-specific T cells of up to 99.6% purity were isolated using the Histamer technology. Rapid and complete disassembly of the T-cell surface-bound A02/CMV Histamer followed by the subsequent dissociation of the pMHC monomers from CD8(+) CTL receptors was achieved using 100 mM L-histidine. The function of CMV-specific T cells enriched by Histamer staining did not differ from CTLs induced by standard T-cell assays. This reversible T-cell staining procedure preserves the functionality of antigen-specific T cells and can be adapted to good manufacturing practice conditions. The pMHC Histamer technology offers full flexibility and fulfills all requirements to generate clinical-grade T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740564     DOI: 10.1093/intimm/dxs059

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

Review 1.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 2.  Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Authors:  Estéfani García-Ríos; Marcos Nuévalos; Francisco J Mancebo; Pilar Pérez-Romero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

3.  β2-microglobulin gene duplication in cetartiodactyla remains intact only in pigs and possibly confers selective advantage to the species.

Authors:  Thong Minh Le; Quy Van Chanh Le; Dung Minh Truong; Hye-Jeong Lee; Min-Kyeung Choi; Hyesun Cho; Hak-Jae Chung; Jin-Hoi Kim; Jeong-Tae Do; Hyuk Song; Chankyu Park
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

4.  Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.

Authors:  Giuseppina Li Pira; Stefano Di Cecca; Simone Biagini; Elia Girolami; Elisabetta Cicchetti; Valentina Bertaina; Concetta Quintarelli; Ignazio Caruana; Barbarella Lucarelli; Pietro Merli; Daria Pagliara; Letizia Pomponia Brescia; Alice Bertaina; Mauro Montanari; Franco Locatelli
Journal:  Front Immunol       Date:  2017-03-23       Impact factor: 7.561

5.  Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.

Authors:  Britta Eiz-Vesper; Britta Maecker-Kolhoff; Rainer Blasczyk
Journal:  Front Immunol       Date:  2013-01-28       Impact factor: 7.561

Review 6.  Virus-Specific T Cells for the Immunocompromised Patient.

Authors:  Amy Houghtelin; Catherine M Bollard
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.